|
|
| ABSTRACT INFORMATION |
| Presenter Information: |
| Presenter 1: |
Name: Scott Grosse
Affiliation:
|
|
| Author Information: |
| Author 1: |
Name: Scott Grosse
Affiliation: CDC
|
|
| Abstract Information: |
| Title: |
Potential Economic Benefits of Preventing Congenital CMV Infections in the United States |
| Primary Track: |
1-EHDI Program Enhancement
|
| Keyword(s): |
Economics, cost |
Abstract: |
The purpose of this study is to present estimates of the economic costs associated with congenital CMV infection. Recently published U.S. estimates of congenital CMV prevalence (0.7%), infant mortality (0.5%) and neurological sequelae, including permanent, bilateral hearing loss of 40 dB or greater without other sequelae (2-4%) and intellectual disability (4-7%) are combined with estimates of the lifetime direct and indirect (productivity) costs in the United States adjusted for inflation to 2005 US dollars associated with infant death ($1.2 million), intellectual disability ($1.2 million), and bilateral moderate to profound pre-lingual hearing loss ($0.5 million) discounted to present values using a 3% discount rate and assuming 1% per year future growth in productivity and incomes. Each case of congenital CMV infection prevented is conservatively calculated to result in $63,000 to $108,000 in averted costs associated with infant mortality, bilateral hearing loss, or intellectual disability. The economic cost associated with such outcomes in each year’s birth cohort with congenital CMV infections is estimated to be $1.9 to $3.2 billion dollars. The potential economic benefits from the primary prevention of congenital CMV infections are enormous. These estimates are conservative because they do not include sequelae for which either cost evidence (mild or unilateral hearing loss) or quantitative epidemiologic evidence (visual impairment) is lacking. |
| Presentation(s): |
Not Available
|
| Handouts: |
Not Available
|
|
|
|
